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Polycyclic aromatic hydrocarbons (PAHs)
from both natural and anthropogenic
sources are ubiquitous in the environment
(1,2). Several of the PAHs are considered
to be carcinogenic, and for this reason,
PAHs are often chemicals of concern at
hazardous waste sites. Examination of
remediation goals established by different
state regulatory agencies for carcinogenic
PAHs in soils indicates that values are fairly
consistent and uniformly low, generally
below 1 mg/kg (Table 1). These remedia-
tion goals are either risk based or, if the
state has determined that method detection
limits (MDLs) are above the risk-based val-
ues, are based on the MDLs. However, as a
practical matter, reviews of background
PAH concentrations show that in many
cases, background concentrations are above
state goals (1,2). If background soil con-
centrations are often above established
goals and consequently, detailed site-specif-
ic evaluation is required on a regular basis,
the remediation goals are oflimited useful-
ness.
The health risk-based remediation goals
for PAHs have been established using stan-
dard procedures and maximum exposure
assumptions and are designed to represent
an upper bound on likely risks. However,
several unresolved issues greatly increase
uncertainty in a risk assessment involving
PAHs (and in risk-based goals) and, more
importantly, make it difficult to determine
whether risk is being over- or underesti-
mated. Issues related to regulatory toxicol-
ogy that affect uncertainty in risk estimates
include the lack of a dose-response esti-
mate for site-of-contact tumors caused by
dermal exposure, questions regarding the
accuracy ofthe available cancer slope factor
for oral exposure, and the lack of an ade-
quate approach for addressing the potency
of mixtures of PAHs. Factors that affect
uncertainty in exposure estimates include
questions regarding the effect of the envi-
ronmental matrix on the availability ofthe
chemicals to a biological receptor and the
lack of information on levels of those
PAHs that are not detected using standard
analytical procedures. A consideration of
these issues is critical to defining the risk
posed by PAHs at hazardous waste sites.
These unresolved issues and their potential
influence on risk assessment results are
described here. In addition, cleanup goals
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for PAHs based on a consideration ofboth
health risks and practicality are proposed.
Table 1. Soil remediation goals proposed by various state regulatory agencies for carcinogenic PAHs
(mg/kg)'
State
Compound NewJerseyb MichiganC Oregond Illinoise Washington
Benzo[a]anthracene 0.66 0.33 0.1 0.009
Benzo[a]pyrene 0.66 0.33 0.1 0.009
Benzo[b]fluoranthene ND 0.33 0.1 0.009
Benzo[kjfluoranthene 0.66 0.33 0.1 0.009
Chrysene 0.66 0.33 0.1 0.009
Dibenzo[ahjanthracene 0.66 0.33 0.1 0.009
Indeno[123-cd1pyrene 0.66 0.33 0.1 0.009
Total carcinogenic PAHsf 4.6 2.3 0.7 0.004 1
(0.2)e
ND, not determined.
aAll states allow adjustments to accountfor site-specific factors including elevated background concen-
trations.
bProposed NewJersey values are based on direct contact exposure to surface soils; proposed stan-
dards for subsurface soils (below 2feet) are higher (100-500mg/kg) (3).
CMichigan values are based on method detection limitsforthese compounds in soils; risk-based values
established based on direct contact exposure were 0.2 mg/kg and were below method detection limits(4).
dOregon values are for residential exposure via direct contact(5).
qThe Illinois Underground Storage Tank Program established a health-based standard of0.004 mg/kg for
carcinogenic PAHs; however,this level is belowthe allowable detection limitforthese compounds of0.2
mg/kg (6). (Most states consider detection limits of around 0.1 mg/kg as reasonable for individual PAHs in
soils.)
These values are the sum of individual criteria forthe seven carcinogenic PAHs, exceptfor NewJersey
(a value of0.66 mg/kg was used forbenzo[bjfluoranthene) and Washington (only a total carcinogenic
PAH value was available) (7).
Background PAH Levels
Many authors have measured levels of
PAHs in the environment (1,2). In gener-
al, the lowest levels are seen in rural areas
away from major highways. The Inter-
national Agency for Research on Cancer
(IARC) reported concentrations of
0.01-10 mg/kg for total PAHs (2) and
Menzie et al. (1) listed concentrations in
forest and rural soils of 0.01-1.3 mg/kg
for carcinogenic PAHs (n = 24). It should
be noted that Menzie et al. (1) includes
benzo[ghilperylene among the carcino-
genic PAHs, although this compound is
not commonly considered to be carcino-
genic (8). IARC (2) notes that somewhat
higher levels of total PAHs are present in
urban soils (1-100 mg/kg) and that indus-
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trial areas have even higher levels (1 to
>100 mg/kg). Likewise, Menzie et al. (1)
report levels of carcinogenic PAHs (plus
benzo[ghilperylene) in urban soils ranging
from 0.06 to 5.8 mg/kg, with a median
value of 1.1 mg/kg (n = 15). These authors
also note that road dust contained very
high levels ofPAHs, with a median of 137
mg/kgand a range of8-336 mg/kg (n = 7).
Issues Influencing RiskAssessments
for PAHs
The original cancer slope factor of 11.5
(mg/kg/day)Y', developed for oral exposure
to benzo[a]pyrene (BaP) and used as the
basis for most PAH risk assessments, was
derived from a study by Neal and Rigdon
(9). Because thisstudy lastedonly 140 days
out of an expected 2 years (730 days), an
adjustment factor of(730/140)3 = 140 was
incorporated into the cancer slope factor,
following EPA policy for less-than-lifetime
studies (10). The power function (Kvalue)
of3 is based on a paper that shows that the
overall tumor incidence in the human pop-
ulation increases with age by a power ofat
least 3 (11). Other researchers do not nec-
essarily agree with the EPA adjustment fac-
tor of K= 3. For example, Crump et al.
(12) assumes K= 4 for tumors in general.
Humans do not have a forestomach, the
tumor site in the Neal and Rigdon study
(9. The human tissues most similar to the
forestomach are the esophagus and the
stomach, and Doll (11) noted Kvalues of
around 6 for both stomach and esophageal
cancer. Consequently, an adjustment fac-
tor as high as (730/140)6 = 20,000 might
be more appropriate for the Neal and
Rigdon data. Ifthis Kvalue of6 is appro-
priate, the corresponding cancer slope fac-
tor would be 800 (mg/kg/day)Y , approxi-
mately 100 times greater than the current
value. Even a Kvalue of4 based on Crump
et al. (12) would mean that the current
cancer slope factor for BaP is too low by a
factor of5.
EPA has revised the cancer slope factor
for oral exposure to BaP to a value of7.3
(mg/kg/day)Yi (13). This value is the geo-
metric mean ofvalues from three analyses
of the Neal and Rigdon data and one
analysis ofa study by Brune et al. (14). All
cancer slope factors from these four analy-
ses were within a range of 4.5-9.0
(mg/kg/day)Y. The Brune et al. (14) study
lasted 2 years, and consequently, no adjust-
ment for length of lifetime was necessary.
However, this study by itself is probably
insufficient to prove that a Kvalue of3 is
appropriate for the Neal and Rigdon (9)
study or that a cancer slope factor of
around 7 (mg/kg/day)Y', and not 35 or
800 (mg/kg/day)Y (the cancer slope factor
associated with a Kvalue of4 or 6, respec-
tively), is appropriate for BaP.
EPA has established an approach for
calculating preliminary remediation goals
(PRGs) for residential exposure via soil
ingestion (15). Using standard EPA
assumptions (15), a target risk level of
10-6, a cancer slope factor of 7.3
(mg/kg/day)Y1, and EPA's equation for cal-
culating PRGs for residential soil, a PRG
for BaP of 0.1 mg/kg is determined.
However, if a higher slope factor such as
800 (mg/kg/day)Y is appropriate, a PRG
as low as 0.001 mg/kg can be calculated.
BaP and other carcinogenic PAHs pro-
duce skin tumors at the site of contact in
mice at very low doses, and evidence sug-
gests that materials containing these com-
pounds are also skin carcinogens for
humans (16). The primary route of expo-
sure to PAHs at many hazardous waste
sites is likely to be direct dermal contact.
There is currently no estimate of the
dose-response relationship between dermal
exposure and site-of-contact cancer, and
this route ofexposure is therefore not con-
sidered in setting remediation goals such as
those listed in Table 1.
Sullivan et al. (17) estimated a dermal
site-of-contact cancer slope factor for BaP
of6.6 x 103 (mg/cm2/day)-' based on data
from a mouse skin-painting bioassay. This
value is somewhat questionable because the
doses used in the skin-painting study pro-
duced over 90% tumor response, and
results presented in Clement (18) indicate
that at these response levels, a very poor
curve fit is achieved (19). Based on discus-
sions with the author of the skin-painting
study, Sullivan et al. (17) assumed that the
exposed area of the mouse back was 30
cm and that three weekly skin-painting
applications led to exposure for 3/7 of a
week, or, in otherwords, that the BaP stays
on the skin for 24 hr after application.
Using these assumptions, a linearized mul-
tistage model (GLOBAL82), and data col-
lected by Schmahl et al. (20) (Table 2), a
dermal site-of-contact cancer slope factor
of 2.3 x 104 (mg/cm2/day)-Y is calculated,
which is fairly close to the Sullivan et al.
(17) estimate. However, information on
the number of tumors per animal was not
available and therefore it is probably more
appropriate to express the cancer slope fac-
tor in terms of mg of chemical per whole
animal exposed dermally. This approach,
essentially eliminating the need to assume
that 30 cm2 of skin was exposed, yields a
slope factor of 760 (mg/exposed
animal/day)Y. Using the cancer slope fac-
tor of 760 (mg/day)Y under the assump-
tion that exposure of equivalent surface
areas ofmouse and human skin will lead to
the same response, and the further assump-
tion that exposed areas will be similar
(approximately 20-25% of the skin is
exposed in EPA exposure estimates for
humans and in skin painting studies on
mice), this value can be used as a site-of-
contact cancer slope factor for humans.
EPA has not developed an approach for
determining allowable soil concentrations
for site-of-contact carcinogens. However,
EPA (21) has developed default assump-
tions for use in evaluating risks associated
with dermal absorption of chemicals.
Using these assumptions and the prelimi-
nary site-of-contact slope factor of 760
(mg/day)Y , a PRG for BaP can be calculat-
ed using the formula:
PRG = TRxAT x 365 days/year
SF x EF x ED x CRx SAx AB
where TR is the target excess cancer risk (1
in 1,000,000 or 10- ); AT is the averaging
time (70 years); SF is the dermal site-of-
contact slope factor [760 (mg/day)-']; EF
is the exposure frequency (central estimate:
40 days/year); ED is the exposure duration
(upper estimate: 30 years); CR is the contact
rate (central estimate: 2 x 10-7 kg/cm2); SA
is the surface area (central estimate: 25%
or 5000 cm2); and AB is the percentage
available from soil relative to availability
from solvent used in the skin painting
study that is the basis for the slope factor
(best professional judgment: 1% or 0.01)
Based on this equation, a PRG that is
protective for direct dermal exposure to
BaP is calculated to be 0.003 mg/kg. This
value is well below risk-based regulatory
limits established for BaP and other car-
TableZ Dose levels and resultsfrom the Schmahl et al. (20) study
Compound Dose Dose levelsa
administered groups (pg/treatment) Cancer incidence, %
Benzolalpyrene Al 1.0 13 (10/81)
A2 1.7 28 (25/88)
A3 3.0 53(43/81)
Controlgroup 0 1 (1/100)
aBaPwas administered to the shaved skin of mice twice a week until the natural death ofthe animals or
until the animals developed a tumor. Atthe start ofthe study, each dose group consisted of 100 animals,
butautolysis limited thetotal number of animals examined in each group.
bNo untreated control group was used in this study. However, based onthe resultsfrom a group exposed
to very low levels of 'noncarcinogenic" PAHs, an incidence rate of 1/100 was assumed for an untreated
control group in calculations.
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cinogenic PAHs, and although prelimi-
nary, suggests that further investigation of
dermal exposure is warranted. The value is
in the same range as the PRG developed
based on ingestion exposure and an oral
slope factor for BaP of 800 (mg/kg/day)Y,
and taken together, these values indicate
that current criteria may pose risks above




The PAHs consist ofa large family ofcom-
pounds with a rather large range of toxic
potency (2,16). PAHs are seldom found
separately in the environment; rather, they
occur as complex mixtures of numerous
compounds. In calculating site risks, EPA
and most state agencies historically separat-
ed the PAHs into two categories: carcino-
gens and noncarcinogens, and treated all
the carcinogenic PAHs as equipotent with
BaP, one of the more potent PAHs. This
approach oversimplifies the situation, as
some ofthe "carcinogenic" compounds are
clearly more potent than others, and some
of the "noncarcinogenic" compounds
appear to have some weak carcinogenic
activity or to act as cancer promoters or
cocarcinogens (16).
Several authors have evaluated the
available data on the carcinogenic potency
of different PAHs and developed toxicity
equivalency factors (TEFs) for the individ-
ual PAHs (18,19,22). These TEFs indicate
the carcinogenic potency of each com-
pound relative to BaP, and multiplying the
concentration of each PAH by the TEF
yields a concentration for the total PAH
mixture that is expressed in terms of an
equivalent concentration (with regard to
toxic potency) of BaP, called BaP equiva-
lents (BaPe uiv). Table 3 presents the TEFs
developed by the various researchers, and
Table 4 indicates the BaP equivalent con-
centrations determined using the historical
EPA approach, the current EPA approach
(22), and the Nisbet and LaGoy (19)
approach on some PAH data from a coal-
tar-contaminated soil sample (23). An eval-
uation of these data indicates that using
appropriate TEFs rather than assuming all
carcinogenic PAHs are equipotent with
BaP would decrease the conservatism in
the risk values by a factor ofapproximately
two to three.
Unreported PAHs
The standard EPA analytical methods
(methods 625 and 8270) test for the pres-
ence of only 17 of the many PAHs likely
to occur in environmental samples. The
other PAHs may contribute to risk and, by
their absence from standard analyses, con-
tribute to the uncertainty in the risk assess-
Table 3. Toxicity equivalency factors proposed for individual PAHs
Clement EPA Nisbet and LaGoy
Compound (18) (22) (19)
Benzo[a]pyrene 1 1 1
Dibenzo[ahjanthracene 1.1 1 5
Benzo[a]anthracene 0.145 0.1 0.1
Benzo[b]fluoranthene 0.140 0.1 0.1
Benzo[k]fluoranthene 0.066 0.01 0.1
Indeno[123-cdlpyrene 0.232 0.1 0.1
Anthracene 0.32 ND 0.01
Benzo[ghilperylene 0.022 ND 0.01
Chrysene 0.0044 0.001 0.01
Acenaphthene ND ND 0.001
Acenaphthylene ND ND 0.001
Fluoranthene ND ND 0.001
Fluorene ND ND 0.001
Methyl naphthalene ND ND 0.001
Naphthalene ND ND 0.001
Phenanthrene ND ND 0.001
Pyrene 0.081 ND 0.001
ND, not determined.
Table 4. A comparison of BaP-equivalent concentrations for a coal-tar-contaminated soil (mg/kg)
Concentration
Detected compound Measured EPAa EPAb Nisbet/LaGoyC
Benzo[alpyrene 39 39 39 39
Dibenzo[ah]anthracene 15 15 15 75
Benzo[a]anthracene 51 51 5 5
Benzo[blfluoranthene 36 36 4 4
Benzo[k]fluoranthene 36 36 0.2 4
lndeno[123-cdlpyrene 36 36 4 4
Anthracene 12 0 0 0.1
Benzo[ghilperylene 31 0 0 0.3
Chrysene 46 46 0.05 0.5
Acenaphthene 2 0 0 <0.01
Acenaphthylene 1 0 0 <0.01
Fluoranthene 58 0 0 0.06
Fluorene 13 0 0 0.01
Methyl naphthalene 3 0 0 <0.01
Naphthalene 6 0 0 <0.01
Phenanthrene 19 0 0 0.02
Pyrene 82 0 0 0.08
Subtotal PAHsd 486
Total
BaP equivalent 259 67 132
aHistorical approach that assumes all carcinogenic PAHs are as potent carcinogens as BaP.
bEPA(22) toxic equivalency factors(TEFs) are based in large part on theTEFs developed by Clement(18).
CBased on the TEFs developed by Nisbet and LaGoy(19).
din this study(23), 74PAHs were detected with a total concentration of 1115 mg/kg. The 17 compounds
included in standard analyses represented 486/1115 or over40% ofthe total amount of available PAHs.
ment. Over the years, considerable effort
has been directed at identifying the car-
cinogenic components of petroleum prod-
ucts, with much of this effort focused on
the PAHs. Consequently, the 17 PAHs
that are analyzed in the standard EPA pro-
cedures may pose a substantial portion of
the risk in most materials. In the one study
reviewed in detail (23), the 17 regularly
analyzed PAHs accounted for 40% of the
total concentration, twice their expected
contribution given that a total of74 PAHs
were detected. However, the converse is
that 60% of the PAHs in this mixture
would be routinely overlooked and conse-
quently not considered in risk estimates.
Furthermore, as noted by Poirier (8), cer-
tain methylated PAHs and PAHs contain-
ing nitrogen or oxygen may be quite
potent carcinogens and if present could
pose substantial risks.
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Bioavailability
To produce toxic effects, PAHs must be
available to the target tissue (i.e., must be
bioavailable). The carcinogenic PAHs are
commonly found in nature in association
with other high molecular weight organic
compounds (e.g., asphaltenes), and these
other compounds probably decrease the
bioavailability of the PAHs. In addition,
PAHs with fairly high octanol-water parti-
tion coefficients tend to bind tightly to
most soils, particularly ifthey have been in
contact with the soils for a considerable
length oftime (21). Consequently, the car-
cinogenic PAHs may not be readily
bioavailable in some situations.
Remediation Goals for Carcinogenic
PAHs
Generic, state, or region-wide remediation
goals for soils are generally established at
the highest ofthe following: 1) risk assess-
ment-based values, with a cancer risk level
of 10-6 commonly used as a target risk
level, 2) MDLs, or 3) regional background
soil levels. A caveat is that ifMDLs are well
above risk-based values, regulatory agencies
may require the use of more sensitive ana-
lytical techniques to achieve remediation
goals that are close to risk-based levels. The
remediation goals listed in Table 1 were
developed with either risk-based values or
method detection limits as the criteria.
Considering that MDLs and the allowable
levels based on previous estimates of resi-
dential risks via soil ingestion are reason-
ably close and that both are above concen-
trations of carcinogenic PAHs in rural
background soils, this approach was appro-
priate. However, evaluation of the issues
affecting risk assessment described above
and of the more detailed review of back-
ground PAH levels by Menzie et al. (1)
suggests that these cleanup criteria are not
reasonable.
A preliminary analysis ofsite-of-contact
risks and reevaluation ofthe oral slope fac-
tor suggests that generic remediation goals
(10 risk) for carcinogenic PAHs may be
close to 0.001 mg/kg, well below even
rural background PAH levels. In addition,
urban soils are probably more representa-
tive ofbackground in areas near hazardous
waste sites, and, as noted by Menzie et al.
(1), background levels of carcinogenic
PAHs in urban soils ranged from 0.06 to 6
mg/kg, with a median of 1 mg/kg.
Considering that risk-based remediation
goals are unachievable, urban background
concentrations in soils appear to be the
most appropriate basis for setting remedia-
tion goals at hazardous waste sites.
In establishing remediation goals based
on background chemical concentrations,
states such as New Jersey and Washington
have generally used upper-bound estimates
of likely background (3,7). Based on the
data reviewed by Menzie et al. (1), upper-
bound estimates of background levels of
carcinogenic PAHs are around 1 mg/kg for
rural and forest soils and 6 mg/kg for
urban soils. Although the value for urban
soils is probably most appropriate, consid-
ering the fact that risk-based cleanup goals
would be several orders of magnitude
below this level, it seems most prudent to
set levels "as low as reasonably achievable."
Consequently, a level of 1 mg/kg as
BaPequiv (rural background) should be used
as a target remediation goal. However,
because there will clearly be cases where
background concentrations exceed this
level, a second-tier value of 10 mg/kg (6
mg/kg rounded to reflect the likely uncer-
tainty in this value) is also recommended.
This second-tier value should be used if,
based on a subjective review, exposure
appears unlikely to involve frequent or
repeated soil contact. For example, levels
below 10 mg/kg would be acceptable as
remediation goals at an industrial site or at
a grass-covered park and might be accept-
able in well-vegetated residential areas.
Substantially higher levels would also be
allowable ifsupported by a risk assessment
and bysite-specific considerations.
Establishing cleanup criteria based on
both practicality and risk is similar to the
approach used for years to establish goals
for radionuclides, namely, setting levels as
low as reasonably achievable (ALARA).
The concept ofALARA was required for
radionuclides because it was recognized
that even very low and therapeutic doses
had some recognizable health risk. PAHs
and radionuclides are similar in that both
are naturally and anthropogenically pro-
duced materials that regularly occur at lev-
els above health risk-based goals.
Discussion and Conclusions
Because large numbers ofsites will contain
PAHs and definition of cleanup criteria
can affect remediation costs by millions of
dollars, it is important to establish reason-
ably achievable remediation goals for
PAHs. Current remediation goals do not
consider several factors that are likely to
substantially impact risk estimates. The
lack of a cancer slope factor for dermal
exposure, questions about the oral cancer
slope factor, and testing for only 17 ofthe
numerous PAHs are all likely to lead to
underestimating risks. On the other hand,
not accounting for differences in the rela-
tive potencyofindividual PAHs and ignor-
ing bioavailability issues may lead to over-
estimating risks. Because ofthese factors, it
may not be possible at this time to firmly
establish a risk-based remediation goal.
However, it also appears that background
soil concentrations may be more appropri-
ate as remediation goals in any case.
Considering the toxicity of this class of
compounds but also considering their
widespread presence in the environment, a
two-tiered system is proposed based on the
concept of ALARA: A tier 1 level of 1
mg/kg of PAHs measured as BaPequivs
recommended as a remediation goal; if
PAHs are below this level, no further
action is required. A tier 2 level of 10
mg/kg of PAHs measured as BaPe is
recommended as well; if PAHs are Below
this level, a subjective evaluation of likely
current and potential future land use is
required. If it appears unlikely that fre-
quent exposure would occur, no further
action is required.
Obviously, higher soil levels may also
be acceptable if, based on a risk assessment,
exposure is determined to be unlikely. For
example, levels well over 100 mg/kg
BaPequiv may not pose a health risk ifcov-
ered with a surface soil layer and digging
into the soils would occur infrequently.
Higher levels may require restrictions on
future land use to ensure safety. Alternative
risk assessment procedures designed to
measure the bioavailability of PAHs from
soils or the effect ofcontaminated soils on
organisms may also be useful in assessing
site risks and in establishing site-specific
cleanup criteria (24,25).
Research to address some of the issues
raised in this article (e.g., oral cancer slope
factors; the effect ofmixtures) is underway
in both government and private laborato-
ries. However, much work remains to be
done, particularly in the areas ofdetermin-
ing an appropriate dermal site-of-contact
slope factor, evaluating the effects ofunan-
alyzed compounds, and in assessing the
bioavailability of PAHs from environmen-
tal media.
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The Forest History Society, publisher ofForest & Conservation
History, offers Alfred D. Bell, Jr., travel grants to those wishing
to utilize its library and archival resources: Records, photographs,
reports, journals, and books. Also a rich bibliographic and
archival information bank for NorthAmerican forest and
conservation history. Preference given to graduate
students and other young scholars.
Writeforinformation andapplication materials to:
FOREST HISTORY SOCIETY
701 Vickers Avenue, Durham, NC 27701
(919) 682-9319
352 Environmental Health Perspectives